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(DHFr) [1] , the enzyme required for the maintenance of tetrahydrofolate (tHF) cofactor pools within cells when 5,10-methylenetHF is oxidized to dihydrofolate (DHF) during the synthesis of thymidylate mediated by thymidylate synthase (tS) [2, 3] . Pralatrexate's pharmacological advantage is based upon its superior properties relative to methotrexate (MtX) as a substrate for the reduced folate carrier (rFC) and folylpolyglutamate synthase (FPgS), resulting in the rapid formation, and accumulation to high levels, of its polyglutamate derivatives that sustain suppression of its target enzyme for long intervals within cells [1, 4] . Unlike its very high affinity for rFC, pralatrexate has a lower affinity for the proton-coupled folate transporter (PCFt) than MtX so that this carrier is unlikely to contribute to the transport of this agent into tumor cells. However, the low affinity for PCFt, the mechanism of intestinal absorption of folates and antifolates, would tend to increase the fecal excretion and clearance of this agent [4] . Pralatrexate is approved for the treatment of relapsed and refractory peripheral t-cell lymphoma and transformed mycosis fungoides [5] [6] [7] and is currently being evaluated for its efficacy in other malignancies [8, 9] .
Pralatrexate is ~10-fold more potent than MtX with continuous exposure, and the difference becomes much greater with a 6-h exposure to the antifolates [4] . However, pralatrexate can be administered parenterally at a weekly dose of 30 mg/m 2 with folic acid supplementation, comparable to the weekly dosing for MtX [5, 10] . Based upon the relative potencies of pralatrexate and MtX, current pralatrexate regimens might be considered comparable to "high-dose" MtX without leucovorin (6(R,S)5-formyltHF) "rescue." these observations indicate that pralatrexate has a greater degree of selectivity than MtX; nonetheless, mucosites is often dose-limiting for the drug [5] . Hence, studies have been initiated and planned to evaluate the impact of "rescue" regimens on the incidence and intensity of the mucosites associated with this agent [11, 12] . the objective of the current study is to determine the extent to which 5-formyltetrahydrofolate alters the activity of pralatrexate, as compared to MtX, using the active "S" isomer (5-formyltHF) and an in vitro protocol that simulates elements of how this folate would be employed in the clinical setting. (Brea, Ca) . the agents were purified as necessary and purity monitored by liquid chromatography as described previously [4, 13] . Pralatrexate was purified using a 5-mm OSD2 4.6 × 250 mm reversedphase column (Waters Spherisorb) by isocratic elution with 100 mM sodium acetate pH 5.5 (solvent a) and 15 % acetonitrile (solvent B). the mobile phase was delivered at 1 ml/min, reaching 100 % solvent B in 30 min. nonlabeled pralatrexate (Folotyn) and (6S)5-formyltHF (Fusilev) were provided by Spectrum Pharmaceuticals (Irvine, Ca). MtX was obtained from Sigma-aldrich (St. louis, MO).
Methods

Cell lines
Hela cells were maintained in folate-free rPMI 1640 medium supplemented with 10 % dialyzed fetal bovine serum (gemini Bio-Products, Ca), 100 U/ml penicillin and 100 μg/ml streptomycin (gibco life technologies, Ca) at 37 °C in a humidified atmosphere of 5 % CO 2 . (6S)5-formyltHF (25 nM) was the folate source in the medium. experimental design and growth inhibition assays experiments were designed to simulate exposures to 5-formyltHF as it is administered in clinical regimens. the experiments evaluated the impact of 5-formyltHF administered after pralatrexate as in "rescue" along with its impact on the activity of the "next" dose of pralatrexate as would occur in a weekly regimen with this agent. the studies were performed within the context of a comparison with MtX at concentrations that produced comparable growth inhibition. the details of each type of experiment are described in the "results" section and the legends to the figures. Hela cells were seeded in 96-well plates at a density of 2 × 10 3 cells/well. at some point, pralatrexate or MtX was added to achieve a spectrum of concentrations. after 6 h, the cells were washed then grown in drug-free medium for 3-5 days. the cells were then assayed by sulforhodamine B staining. absorbance was measured at 540 nM with the VerSamax plate reader (ge Intelligent Platforms, Charlottesville, Va).
Measurement of total cellular folate and antifolate levels
For determination of total cellular folates, Hela cells were grown for a week in folate-free medium supplemented with gat (0.2 mM glycine, 0.1 mM adenosine and 0.01 mM thymidine) to deplete endogenous folates. the cells were then replated in medium supplemented with 25 nM [ 3 H] (6S)5-formyltHF. One portion was maintained in this medium, and the other portion was exposed to 4 μM [ 3 H] (6S)5-formyltHF for 24 h weekly. after 4 weeks (four, 7 day cycles) the cells were washed in ice-cold HBS buffer (20 mM Hepes, 140 mM naCl, 5 mM KCl, 2 mM MgCl 2 and 5 mM dextrose; adjusted with 1 n naOH to achieve a pH of 7.4) and then digested with 500 μl of 0.2 n naOH at 65 °C for 45 min. twenty μl was used for protein determination by the bicinchoninic acid protein assay (Pierce Chemical, Il), 400 μl for assessment of tritium on a liquid scintillation spectrometer. 
Results
analysis of 5-formyltHF "rescue" of Hela cells as a function of time between exposure to antifolates and exposure to 5-formyltHF On day 1, Hela cells were incubated for 6 h with a spectrum of pralatrexate or MtX concentrations. twenty-four or 48 h later, the cells were incubated with 1 μM 5-formyltHF for 24 h, following which the cells were grown without either agent but in presence of 25 nM 5-formyltHF, representative of the "normal" blood folate level. the IC 50 (the antifolate concentration at which growth was 50 % that of cells not exposed to drugs) for pralatrexate (Fig. 1a) or MtX (Fig. 1b) was not affected by these exposures to 5-formyltHF. Comparing the two panels, it can be seen that pralatrexate was ~130-fold more potent than MtX under these conditions. the impact of the 5-formyltHF concentration on "rescue" Because a 24-h interval was sufficient to sustain the cytotoxicity of MtX and pralatrexate at an extracellular concentration of 1 μM 5-formyltHF, studies evaluated the impact of increasing the 5-formyltHF concentration. On day 1, Hela cells were incubated for 6 h with pralatrexate or MtX; 24 h later, the cells were incubated with 1-16 μM 5-formyltHF were maintained continuously in 25 nM 5-formyltHF. growth in the absence of drug is indicated as 100 %. the vertical line intercepts the x axis at the concentration at which growth inhibition is 50 % of the level of growth in the absence of drug (IC 50 ). Data are the mean ± SeM from three independent experiments. c Hela cells were incubated with a spectrum of pralatrexate or MtX concentrations for 6 h. after 24 h, the cells were exposed to 5-formyltHF at the indicated concentrations for 24 h and then grown in 25 nM 5-formyltHF for an additional 4 days. Control cells were maintained in 25 nM 5-formyltHF. the y axis is the ratio of the IC 50 of the cells exposed to ≥1 μM 5-formyltHF to cells grown in 25 nM 5-formyltHF. Cells were always washed after each manipulation. Data are the mean ± SeM from three independent experiments 1 3 for 24 h, following which the cells were grown for an additional 4 days in 25 nM 5-formyltHF. as indicated in Fig. 1c , the pralatrexate and MtX IC 50 ratios (the ratio of the IC 50 of the cells exposed to ≥1 μM 5-formyltHF to cells grown in 25 nM 5-formyltHF) were unchanged at 5-formyltHF concentrations up to 4 μM; the small increase in the pralatrexate IC 50 at 4 μM was not significant. Comparing the average IC 50 of the lowest three with the average of the highest three 5-formyltHF concentrations, there was only a small increase in the pralatrexate IC 50 (47 ± 2 vs 71 ± 2 nM, P = 0.006) and the MtX IC 50 (2.9 ± 0.15 vs 3.8 ± 0.2 μM, P = 0.08).
an analysis of the "protective" potential of 5-formyltHF on the subsequent exposure to pralatrexate and MtX in Hela cells the previous experiments indicated that a single 6-h incubation with pralatrexate or MtX followed 24 h later by growth in up to 4 μM 5-formyltHF did not alter the activities of these antifolates. Other studies assessed the extent to which exposure to the folate prior to the exposure to the antifolates affects the antitumor activity. Hela cells were exposed for 24 h to 1 μM 5-formyltHF and then replated in medium with 25 nM 5-formyltHF 24, 48 or 72 h before a 6 h incubation with pralatrexate or MtX. as indicated in Fig. 2a , pralatrexate activity was decreased ~twofold (IC 50 increased from ~28 to ~60 nM) when cells were exposed to the drugs 24 or 48 h after treatment with 5-formyltHF. MtX activity was comparably decreased (IC 50 increased from ~3 to ~7 μM) under similar conditions (Fig. 2b) . the activities of both drugs were fully restored when exposure to the antifolates was delayed until 72 h after exposure to the 5-formyltHF.
antifolate "protection" as function of the 5-formyltHF concentration to determine the extent to which protection was dependent upon the 5-formyltHF concentration, Hela cells were exposed to from 1 to 16 μM 5-formyltHF for 24 h, then washed and incubated in medium with 25 nM 5-formyltHF; 72 h later, the cells were incubated for 6 h with pralatrexate or MtX then grown in absence of antifolate until the end of the assay. Figure 3a indicates that the IC 50 ratio for pralatrexate was unchanged up to 8 μM 5-formyltHF; the small increase at 16 μM 5-formyltHF was not significant. Similarly, while there was a trend toward an increase in the IC 50 ratio for MtX at the highest 5-formyltHF concentrations, this did not reach statistical significance.
next, the cumulative effect of repeated exposures to 5-formyltHF on pralatrexate and MtX activities was assessed. Hela cells were subjected to 24-h incubations with 4 μM 5-formyltHF weekly for 4 weeks. Seventy-two hours after the last (4th) exposure, the cells were incubated with pralatrexate or MtX for 6 h then replated with 25 nM 5-formyltHF for an additional 5 days. Figure 3b indicates that pralatrexate activity was minimally affected by multiple exposures to 5-formyltHF. Figure 3c illustrates the slope of the IC 50 ratio as a function of the extracellular concentration of 5-formyltHF. While the slope for pralatrexate is significant (P = 0.03, Panel c), there was only a negligible increase in the IC 50 ratio at 4 μM 5-formyltHF. the pattern for MtX was different as indicated in Fig. 3b, c . the IC 50 ratio increased as the 5-formyltHF concentration increased reaching a level >2.5-fold greater for cells growing in 4 μM as compared to 25 nM 5-formyltHF (P = 0.005, Fig. 3c ). the inset to Fig. 3c amplifies the slope of the IC 50 ratios within the 4 μM range. It can be seen that the slope of the MtX IC 50 ratio as a function of the extracellular 5-formyltHF concentration exceeded that of pralatrexate by a factor of 10 (0.4 vs 0.04, P = 0.01). Hence, loading cells with 5-formyltHF clearly impacts on the activity of MtX but has a negligible effect on pralatrexate activity particularly at concentrations of the folate to which cells are exposed in clinical rescue regimens (see "Discussion").
Cumulative effect of 5-formyltHF on total cell folate the impact of the multiple exposures to 5-formyltHF on total cell folate was assessed by first depleting cells of endogenous folates by growth in gat for 1 week. the cells were then grown continuously with 25 nM Figure 4a indicates that there was a small (16 %) but significant increase in the total folate pool (58.8 ± 1.0 vs 68.3 ± 2.7 pmol/mg of protein, respectively, P = 0.02) after the fourth cycle.
the impact of four weekly exposures to 5-formyltHF on pralatrexate and MtX accumulation to evaluate the impact of four cycles of exposure to 5-formyltHF, as described above, on the accumulation of the antifolates, 72 h after the 4th exposure to 5-formyltHF, cells were exposed to 0. ]pralatrexate over the 6-h incubation, consistent with the more efficient transport and polyglutamation of the latter antifolate. these concentrations also reflected the differences in IC 50 's for these agents.
Discussion
Pralatrexate has a much higher therapeutic index than MtX. However, the degree of toxicity is far less than might be expected from an agent that is so potent relative to MtX but can be administered weekly intravenously at a dose only slightly less than that of MtX [6] . While sharing the same target, DHFr, pralatrexate's eightfold to 10-fold higher affinity for rFC, and 10-fold greater catalytic activity mediated by FPgS, relative to MtX, results in the formation and accumulation of high levels of its active polyglutamate derivatives that are retained in tumor cells and produce sustained inhibition of its target enzyme [1, 4] . this is illustrated by the observation that a 6-h incubation with MtX required a ~50-fold higher extracellular concentration than pralatrexate to achieve a comparable intracellular level and growth inhibition. However, the mucosites associated with pralatrexate can be dose-limiting and an impediment to its use. this has raised the possibility that a leucovorin "rescue" regimen might improve the clinical utility of this agent [12] . Some patients have been treated with a "rescue" regimen (a single 50-mg dose 24 h after pralatrexate) with amelioration of toxicity and, while anecdotal, antitumor activity was preserved at least in part [12] .
Previous studies from this laboratory described the adverse impact of 5-formyltHF on the activities of a variety of antifolates [14, 15] . the impact on pemetrexed activity was shown to be due to inhibition of the formation of polyglutamate derivatives of this agent required for inhibition of its target enzymes [14] . recently, a similar phenomenon was observed for new generation garFtase inhibitors that also have a high affinity for FPgS [16] . When the exposure to MtX is brief, its activity is very sensitive to the cellular folate pool. this reflects the much lower affinity of MtX for FPgS relative to pralatrexate and the much longer time required to accumulate its polyglutamate derivatives in cells [14, 17, 18] . It was important to understand the effect that 5-formyltHF might have on the activity of pralatrexate in order to minimize, as much as possible, a negative impact on its efficacy. the natural (S) isomer of 5-formyltHF was utilized in the current study. the unnatural (D) isomer has essentially no biological activity; it is a very poor substrate for rFC [19] and what does enter cells cannot be metabolized. Hence, the concentrations of (6S)5-formyltHF employed in this study are chemically equivalent to half the concentration of the racemic mixture but equal to the biologically active fraction. the exposures to 5-formyltHF encompassed and far exceeded the concentration of this folate, and 5-methyltetrahydrofolate to which it is rapidly converted, achieved in "rescue" regimens in vivo. For instance, following a 50-mg intravenous dose of leucovorin, the same dose as in the case reports with pralatrexate described above [12] , the peak (6S)5-formyltHF blood level was ~4.4 μM with a t ½ of 32 min, the peak 5-methyltHF level was ~1.6 μM with a t ½ of 224 min so that at 6 h the former was ~0.02 μM and the latter was ~0.8 μM; by 12 h, the latter was ~0.2 μM [20] . When leucovorin was administered p.o. at 25 mg every 8 h, the mean 5-methyltHF blood level was only ~0.7 μM at 48 h [20] . likewise, after an intravenous dose of 10 or 25 mg/m 2 leucovorin, the peak 5-methyltHF blood levels were 0.23 and 0.6 μM, respectively, with an average t ½ of 6.6 h. With p.o. dosing, the peak 5-methyltHF levels were 0.32, 0.47 μM, respectively, with an average t ½ of 3.1 h [21] . at these 5-methyltHF blood levels, there would be essentially no impact on pralatrexate activity. a 24-h interval between exposure to the antifolates and 5-formyltHF in the current study was sufficient to sustain full growth inhibition by MtX and pralatrexate to a 5-formyltHF concentration of 4 μM with only a small (50 %) increase in IC 50 at 16 μM 5-formyltHF. On the other hand, when the impact of 5-formyltHF on the "next" dose of antifolate was considered, a 72-h delay after exposure to 5-formyltHF was necessary to preserve antifolate activities. even when the exposure to 5-formyltHF was repeated weekly for 4 weeks, there was no increase in the pralatrexate IC 50 ratio at blood levels that exceeded those achieved in "rescue" regimens; however, the MtX IC 50 increased to 2.5-fold as the 5-formyltHF concentration was increased to 4 μM. Hence, it would appear that a critical element in preserving antifolate activity is the delay between 5-formyltHF and the next dose of antifolate. Indeed, in a weekly regimen, the delay would be 4 days if the "rescue" interval was restricted to 24 h. the rationale for high-dose MtX with leucovorin "rescue," and its putative selectivity, is based upon elements at the tumor, cellular and biochemical levels [3, 22] . High concentrations of drug facilitate passive diffusion into the poorly perfused interstitium of solid tumors. the subsequent provision of much lower doses of leucovorin poorly penetrate tumors but are readily accessible to precursor cells of the intestine and bone marrow with their intact vascular system. likewise, high concentrations of MtX would passively diffuse into tumor cells with impaired transport due to low expression or loss-of-function mutations of rFC. alternatively, antifolates could enter cells by the proton-coupled folate transporter (PCFt) [2, 4] . the low concentration of leucovorin during "rescue," which enters cells via the same transporter would have limited access to the tumor cells but would readily enter normal tissues with intact rFC. at the biochemical level, MtX polyglutamate derivatives are potent direct inhibitors of tS and phosphoribosylaminoimidazolecarboxamide formyltransferase [23] [24] [25] . this interferes with the utilization of 5,10-methylenetHF and 10-formyltHF, respectively, formed by the interconversion of leucovorin [26] . However, utilization of these one-carbon donors in bone marrow and intestine is less impeded since only low levels of MtX polyglutamate derivatives accumulate in these cells [27] [28] [29] [30] . Finally, the interconversion of leucovorin to DHF results in the displacement of the monoglutamate of MtX from DHFr reactivating tetrahydrofolate synthesis. However, this does not occur when high levels of MtX polyglutamates accumulate in tumor cells [31, 32] . there is no information, as yet, as to the extent to which pralatrexate polyglutamates are direct inhibitors of tetrahydrofolate cofactor-requiring enzymes in cells.
there are preclinical in vivo data that support the concept that leucovorin "rescue" diminishes the toxicity, while preserving the activity, of MtX and aminopterin [33, 34] . leucovorin "rescue" clearly decreases the toxicity of high-dose MtX regimens; however, the extent to which the antitumor activity of MtX is diminished is uncertain. One clinical study compared standard-dose MtX (40 mg/ m 2 weekly for 8 weeks) with or without low-dose leucovorin "rescue" (10 mg/m 2 p.o. every 6 h, starting 24 h after MtX, for four doses) in patients with squamous cell head and neck cancer. leucovorin decreased drug toxicity but also diminished antitumor activity (response rate, 17.1 and 36.7 %, respectively, P = 0.047) [35] . Data in the current report indicate that there is a greater adverse impact of loading cells with folates on MtX than pralatrexate antitumor activities. Because of the high therapeutic index of pralatrexate relative to MtX, it may be that very modest doses of 5-formyltHF administered over short intervals will obviate the mucosites without an adverse impact on pralatrexate's therapeutic efficacy, as suggested by the initial report described above [12] .
Finally, the observations in this report are focused on one cell line. It is possible that the critical intervals between exposures to antifolates and 5-formyltHF, along with the magnitude of the suppressive effects of 5-formyltHF, may vary among cells of different origin. However, irrespective of these considerations, these studies indicate that the impact of "rescue" with intermittent exposures to 5-formyltHF will be less for pralatrexate than for MtX. Since, as indicated above, there is evidence that leucovorin "rescue" is associated with decreased efficacy of MtX, this represents an important advantage for this next-generation DHFr inhibitor.
